Comparative Pharmacology
Head-to-head clinical analysis: LEVAQUIN versus VIGAMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVAQUIN versus VIGAMOX.
LEVAQUIN vs VIGAMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination.
Fluoroquinolone antibiotic that inhibits DNA gyrase and topoisomerase IV, preventing bacterial DNA replication.
LEVAQUIN (levofloxacin) 500 mg orally or intravenously once daily for most infections; 750 mg orally or intravenously once daily for more severe infections or complicated urinary tract infections.
1 drop in affected eye(s) every 4 hours while awake for 7 days; may increase to 1 drop every 2 hours on day 1.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged to 48-108 hours in severe renal impairment (CrCl <20 mL/min).
Terminal elimination half-life: 12-14 hours; clinically relevant for once-daily dosing
Primarily renal excretion as unchanged drug (approximately 87% in urine); fecal excretion accounts for <5% as unchanged drug and metabolites; biliary excretion is minimal.
Renal: 70-80% unchanged; biliary/fecal: 15-20%
Category C
Category C
Antibiotic (Fluoroquinolone)
Antibiotic (Fluoroquinolone)